Brain Switch Discovery Could Revolutionize Obesity Drugs and Weight Loss

Scientists have mapped how two opposing approaches to the same brain receptor both trigger weight loss, offering new insight into the mechanisms behind modern obesity treatments. According to research published in Nature Metabolism by scientists at the Institute of Metabolic Science, University of Cambridge, activating a protein receptor called GIPR in the brainstem reduces appetite, while blocking that same receptor in the hypothalamus produces a similar weight-loss effect through a different mechanism.

Understanding the GIPR Brain Switch Puzzle

More than a billion people worldwide live with obesity, which raises the risk of type 2 diabetes, cardiovascular disease, and cancer, according to the University of Cambridge study. While dietary changes and exercise help, achieving substantial weight loss remains difficult for many patients. A new generation of medications has emerged that targets specific receptors involved in appetite and blood sugar regulation.

Several widely used medications, such as Wegovy and Ozempic, activate the glucagon-like peptide 1 receptor, known as GLP-1R. Other treatments act on both GLP-1R and the glucose-dependent insulinotropic polypeptide receptor, or GIPR. This second target presented researchers with a distinct puzzle because different drugs utilize opposite tactics on the same receptor.

Medications including Mounjaro and Zepbound activate GIPR, whereas other treatments like MariTide block it. Despite producing opposite pharmacological effects on the exact same receptor, both strategies promote weight loss. The Cambridge team set out to discover why by tracking GIPR activity across different neurological regions in mice.

Brainstem Activation Versus Hypothalamic Blocking

To pinpoint where these drugs act, the researchers used genetically engineered mice that lacked GIPR in specific areas. In one cohort, the brainstem—the lower part of the brain situated right above the spinal cord that participates in nausea and appetite regulation—was missing the receptor. Another group lacked GIPR in the hypothalamus, a region involved in regulating hunger and body weight. A third group served as control subjects.

The scientists treated the animals with combinations of GIPR agonists that activate the receptor, GIPR antagonists that block it, and GLP-1 medications. They monitored food intake, body weight, fat mass, blood sugar control, and brain activity. The results demonstrated that GIPR agonists work primarily through the brainstem, reducing appetite and body weight when activated in that zone.

Conversely, GIPR antagonists followed a different route through the hypothalamus. In that region, GIPR appears to function as a brake that limits how strongly the brainstem responds to signals indicating that the body is full. Blocking the receptor releases that brake, allowing fullness signals to exert a stronger effect.

Implications for Future Drug Combinations

The Cambridge experiments also revealed that blocking GIPR could enhance the effects of emerging medicines that target the amylin receptor. This suggests that GIPR antagonists might eventually strengthen several distinct classes of obesity treatments when paired correctly. Furthermore, the findings help explain the mechanisms behind therapies like MariTide and point toward more powerful drug combinations.

In a separate study published in Cell Metabolism, researchers at the Sahlgrenska Academy at the University of Gothenburg identified a specific group of nerve cells in the brain’s dorsal vagal complex that drive the weight-loss benefits of semaglutide. By isolating these Adcyap1+ neurons, the Gothenburg team induced appetite reduction and fat loss in mice without triggering common side effects like nausea and muscle loss.

This suggests that these nerve cells control the beneficial effects of semaglutide. Consequently, our team has pinpointed a distinct subset of neurons essential for the weight and appetite outcomes produced by semaglutide, yet this population seems largely uninvolved in adverse reactions like nausea.